In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including: ROS1-gene fusions in advanced lung cancer ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors Advantages of RNA- vs DNA-based next-generation sequencing Program faculty: Jessica J. Lin, MD Attending Physician Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Alice T. Shaw, MD, PhD Chief, Strategic Partnerships Attending Physician, Thoracic Oncology Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts Resources: To download the slides associated with this podcast discussion, please visit the program page Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
